The Lighthouse II clinical trial was a randomised double-blind placebo controlled trial that sought to investigate whether the combination medicine Triumeq (dolutegravir 50mg, abacavir 600mg, lamivudine 300mg), is safe and effective in delaying the progression of ALS/MND. Triumeq is very commonly prescribed for patients with HIV. The secondary aim of this study was to assess patient's health outcomes whilst taking this medication.
The results, announced at the ENCALS 2025 meeting in Turin, showed that unfortunately, there was no benefit of taking the drug Triumeq for people with ALS when compared with placebo on survival, the primary outcome measure. Due to these disappointing results, the decision has been made to terminate the study.
Further information
Profile for Dr Ammar Al-Chalabi, King's College London (external website)
Profile for Professor Suvankar Pal
Triumeq clinical trial information on the MND Association website (external website)
